219 related articles for article (PubMed ID: 18487582)
1. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
Abou-Jawde RM; Oberoi SS
J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
[No Abstract] [Full Text] [Related]
2. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
[TBL] [Abstract][Full Text] [Related]
3. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
4. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
5. Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients.
Villa A; Parazzini F; Scarfone G; Guarnerio P; Bolis G
Br J Cancer; 1999 Jan; 79(2):373-4. PubMed ID: 9888485
[No Abstract] [Full Text] [Related]
6. Carboplatin.
Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623
[No Abstract] [Full Text] [Related]
7. Second-line chemotherapy of epithelial ovarian cancer.
Markmon M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin for the treatment of ovarian cancer.
Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
Expert Opin Investig Drugs; 2015; 24(9):1275-86. PubMed ID: 26125301
[TBL] [Abstract][Full Text] [Related]
9. Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer.
Markman M
Gynecol Oncol; 1999 Jun; 73(3):469-70; author reply 470-2. PubMed ID: 10366485
[No Abstract] [Full Text] [Related]
10. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Markman M
Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
[TBL] [Abstract][Full Text] [Related]
11. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
[TBL] [Abstract][Full Text] [Related]
12. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.
Vergote I; Amant F
Gynecol Oncol; 2006 Sep; 102(3):415-7. PubMed ID: 16979430
[No Abstract] [Full Text] [Related]
13. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
14. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
Munkarah A
Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
[No Abstract] [Full Text] [Related]
15. Clinical application of oxaliplatin in epithelial ovarian cancer.
Fu S; Kavanagh JJ; Hu W; Bast RC
Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
[TBL] [Abstract][Full Text] [Related]
16. Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP; Schilder RJ
Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
[TBL] [Abstract][Full Text] [Related]
17. Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
Patsner B
Gynecol Oncol; 2008 Jan; 108(1):254-5; author reply 255. PubMed ID: 17963827
[No Abstract] [Full Text] [Related]
18. Narrow-band imaging in laparoscopic management of recurrent platinum sensitive ovarian cancer.
Gagliardi ML; Polito S; Fagotti A; Fanfani F; Scambia G
J Minim Invasive Gynecol; 2013; 20(1):10-2. PubMed ID: 23312240
[No Abstract] [Full Text] [Related]
19. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
[TBL] [Abstract][Full Text] [Related]
20. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies.
Tomao F; Marchetti C; Romito A; Di Pinto A; Di Donato V; Capri O; Palaia I; Monti M; Muzii L; Benedetti Panici P
Expert Opin Pharmacother; 2017 Oct; 18(14):1443-1455. PubMed ID: 28521614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
